Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
Bristol-Myers Stock Jumps on FDA Approval for New Schizophrenia Drug
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...
Bristol-Myers Squibb stock jumps on schizophrenia drug approval
Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...
FDA approves 1st new drug for schizophrenia in more than 30 years
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...
FDA approves new schizophrenia drug
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.
This FDA-approved drug promises a new way to treat schizophrenia
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...
US FDA approves Bristol Myers' schizophrenia drug
Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last ...
FDA approves new kind of drug for schizophrenia
The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and ...
STAT14h
FDA approves schizophrenia drug that could alter how disorder is treated
Cobenfy was approved to reduce the psychotic symptoms associated with schizophrenia. It is a new type of medicine that works ...
Managed Healthcare Executive53m
FDA Approves the Oral Medication KarXT for Schizophrenia
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.